10X Genomics Inc
TXG20.460USD
+1.170+6.07%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.59BMarket Cap
LossP/E TTM
More Details of 10X Genomics Inc Company
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
10X Genomics Inc Info
Ticker SymbolTXG
Company name10X Genomics Inc
IPO dateSep 12, 2019
CEOSaxonov (Serge Wilson)
Number of employees1306
Security typeOrdinary Share
Fiscal year-endSep 12
Address6230 Stoneridge Mall Road
CityPLEASANTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94588
Phone19254017300
Websitehttps://www.10xgenomics.com/
Ticker SymbolTXG
IPO dateSep 12, 2019
CEOSaxonov (Serge Wilson)
Company Executives of 10X Genomics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.04M
-13261.00%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+15357.00%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+45563.00%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+15357.00%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
36.41K
-8283.00%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+15357.00%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
28.62K
+15357.00%
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.04M
-13261.00%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+15357.00%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+45563.00%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+15357.00%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
36.41K
-8283.00%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+15357.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Consumables
127.89M
85.83%
Instruments
12.00M
8.05%
Services
8.13M
5.45%
License and royalty revenue
983.00K
0.66%
By RegionUSD
Name
Revenue
Proportion
United States
77.25M
51.84%
Europe, the Middle East and Africa
41.62M
27.94%
China
15.19M
10.19%
Asia Pacific
12.32M
8.27%
Americas
2.63M
1.76%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Consumables
127.89M
85.83%
Instruments
12.00M
8.05%
Services
8.13M
5.45%
License and royalty revenue
983.00K
0.66%
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.38%
ARK Investment Management LLC
10.21%
BlackRock Institutional Trust Company, N.A.
6.68%
Fidelity Management & Research Company LLC
6.19%
Millennium Management LLC
4.67%
Other
60.88%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.38%
ARK Investment Management LLC
10.21%
BlackRock Institutional Trust Company, N.A.
6.68%
Fidelity Management & Research Company LLC
6.19%
Millennium Management LLC
4.67%
Other
60.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.34%
Investment Advisor/Hedge Fund
27.24%
Hedge Fund
14.51%
Research Firm
6.24%
Bank and Trust
5.01%
Venture Capital
1.88%
Individual Investor
1.80%
Family Office
0.84%
Pension Fund
0.54%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
684
126.11M
108.27%
-15.61M
2025Q3
675
117.21M
102.45%
-24.61M
2025Q2
669
120.42M
108.39%
-15.20M
2025Q1
687
115.67M
104.27%
-8.84M
2024Q4
689
107.08M
98.92%
-12.41M
2024Q3
682
106.90M
100.39%
-9.08M
2024Q2
691
105.36M
99.70%
-5.09M
2024Q1
762
106.36M
101.17%
-3.12M
2023Q4
817
100.80M
96.01%
-9.73M
2023Q3
835
96.86M
93.80%
-12.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
13.25M
11.38%
+834.27K
+6.72%
Sep 30, 2025
ARK Investment Management LLC
11.89M
10.21%
-2.00M
-14.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
7.78M
6.68%
+194.98K
+2.57%
Sep 30, 2025
Fidelity Management & Research Company LLC
7.21M
6.19%
-430.91K
-5.64%
Sep 30, 2025
Millennium Management LLC
5.44M
4.67%
+2.55M
+88.57%
Sep 30, 2025
Sumitomo Mitsui Trust Bank, Limited
5.38M
4.62%
-636.74K
-10.58%
Sep 30, 2025
Amova Asset Management Co., Ltd.
5.38M
4.62%
+5.38M
--
Sep 30, 2025
Wellington Management Company, LLP
4.29M
3.68%
+2.39M
+126.60%
Sep 30, 2025
Quantinno Capital Management LP
3.49M
3%
+1.26M
+56.37%
Sep 30, 2025
BofA Global Research (US)
3.30M
2.83%
+393.85K
+13.55%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ARK Genomic Revolution ETF
4.02%
Simplify Health Care ETF
2.89%
Janus Henderson Small Cap Growth Alpha ETF
1.66%
Global X Genomics & Biotechnology ETF
1.56%
ARK Innovation ETF
1.3%
WisdomTree BioRevolution Fund
1.28%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.17%
Harbor Long-Short Equity ETF
0.61%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.53%
Invesco NASDAQ Future Gen 200 ETF
0.52%
View more
ARK Genomic Revolution ETF
Proportion4.02%
Simplify Health Care ETF
Proportion2.89%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.66%
Global X Genomics & Biotechnology ETF
Proportion1.56%
ARK Innovation ETF
Proportion1.3%
WisdomTree BioRevolution Fund
Proportion1.28%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion1.17%
Harbor Long-Short Equity ETF
Proportion0.61%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.53%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.52%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of 10X Genomics Inc?
The top five shareholders of 10X Genomics Inc are:
The Vanguard Group, Inc. holds 13.25M shares, accounting for 11.38% of the total shares.
ARK Investment Management LLC holds 11.89M shares, accounting for 10.21% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.78M shares, accounting for 6.68% of the total shares.
Fidelity Management & Research Company LLC holds 7.21M shares, accounting for 6.19% of the total shares.
Millennium Management LLC holds 5.44M shares, accounting for 4.67% of the total shares.
The Vanguard Group, Inc. holds 13.25M shares, accounting for 11.38% of the total shares.
ARK Investment Management LLC holds 11.89M shares, accounting for 10.21% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 7.78M shares, accounting for 6.68% of the total shares.
Fidelity Management & Research Company LLC holds 7.21M shares, accounting for 6.19% of the total shares.
Millennium Management LLC holds 5.44M shares, accounting for 4.67% of the total shares.
What are the top three shareholder types of 10X Genomics Inc?
The top three shareholder types of 10X Genomics Inc are:
The Vanguard Group, Inc.
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of 10X Genomics Inc (TXG)?
As of 2025Q4, 684 institutions hold shares of 10X Genomics Inc, with a combined market value of approximately 126.11M, accounting for 108.27% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 5.82%.
What is the biggest source of revenue for 10X Genomics Inc?
In FY2025Q3, the Consumables business generated the highest revenue for 10X Genomics Inc, amounting to 127.89M and accounting for 85.83% of total revenue.
